• 杨慧.嵌合抗原受体 T 细胞治疗在虚弱恶性血液病患者中的挑战与管理策略[J].内科急危重症杂志,2025,31(2):165-170
    DOI:10.11768/nkjwzzzz20250214
    CN KeyWords:  虚弱  恶性血液病  嵌合抗原受体T细胞治疗
    EN KeyWords:
    Fund Project:山西省自然科学基金面上项目(202303021211224;202403021211164)
    Author:
    View Counts: 1175
    PDF Download Counts: 1739
          摘要 嵌合抗原受体T(CAR-T)细胞疗法已成为恶性血液病的重要治疗手段。然而,虚弱患者由于生理功能衰退、合并症多及免疫微环境的改变等,可能面临更高的治疗风险及更差的预后。本综述旨在探讨虚弱的评估工具,总结虚弱患者的临床疗效数据,分析虚弱对疗效的影响机制,并提出基于虚弱患者的管理策略,以期优化治疗结局。
    EN Abstract:
          Abstract himeric antigen receptor (CAR)-T cell therapy has become an important treatment for malignant haematological diseases. However, frail patients may face higher therapeutic risks and poorer prognosis due to physiological decline, multiple comorbidities and altered immune microenvironment. The aim of this review is to explore assessment tools for frailty, summarize clinical outcome data of frail patients, analyze the mechanisms by which frailty affects outcome, and propose frailty-based management strategies with a view to optimising treatment outcomes in frailty.